Daily Chart

Send a Tweet

$NVS
#Novartis Ag-adr
NVS
Novartis Ag-adr
Look for:
NVS
Pre-Market Movers: $NVO,$FCL,$PCZ,$GSK,$ERTS,$HBC,$DDR,$DB,$GFA,$NVS...more
NVS
Novartis $NVS in-licenses a mid-to-late-stage experimental hepatitis C drug from a private Swiss co. Gains exclusive WW rights,except Japan.
NVS
Monday February 8 2010 MACD Sell Signal $ALXN $BAP $GILD $MCD $ROST $NVS $PETD $PII $LKFN $NTY #economics
NVS
@drpdtapp yes $NVS have Afinitor and $GSK have pazopanib. There are 6 approved in renal cc now
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. $RHHBY $NVS (@mhuckman)
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. Crew tweaking lights now. $RHHBY $NVS
NVS
Allergan’s Looking Real Pretty Right Now http://cnbc.com/id/35238576 $ABT $ACL $AGN $NVS #StockPicks #StockMarket
NVS
RT@MhuckmanRoche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHH
NVS
Roche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHHBY $NVS
NVS
Pfizer Earnings By the Numbers http://cnbc.com/id/35196988 $AMGN $BIIB $GENZ $GILD $MRK $NVS $PFE $WAT #StockMarket
NVS
$NVS $CSBTF Hypertension Market Will Be Constrained Through 2018 by Pipeline Containing Few Novel Emerging Therapies http://bit.ly/c3boXR
NVS
Is Genentech/Roche turning a blind eye to a marketing/PR opportunity for Lucentis/Avastin? Vote in the poll. http://bit.ly/9VSjxq $NVS
NVS
RT @adamfeuerstein: @mhuckman: Kaiser "real-world" study:Avastin = Lucentis for AMD. $NVS $RHHBY Genentech: Only L proven safe,eff
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
RT @mhuckman: Kaiser "real-world" study:Avastin works as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.




Novartis Ag-adr - NVS Insiders

No Insiders

We have no insiders for Novartis Ag-adr right now.

Know someone who is an insider on Novartis Ag-adr?
Let us know.

Novartis Ag-adr - NVS information

...
135,000 Employees
Last Reported Date: 07/17/14
Founded in 1895
Last $88.41 USD
Change Today -0.72 / -0.81%
Volume 693.2K
As of 8:04 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVS) Snapshot

Open
$88.77
Previous Close
$89.13
Day High
$88.77
Day Low
$88.21
52 Week High
07/1/14 - $91.66
52 Week Low
07/30/13 - $71.00
Market Cap
239.3B
Average Volume 10 Days
1.1M
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
$2.76
Dividend Yield
3.12%
Request Investor Kit
NVS:US Advanced Stock Chart

novartis ag-adr (NVS) Related Bloomberg News

Fed Taper Question Keeps U.S. Corporate Bond Sales Below Average
Novartis Jury Awards $10.45 Million for Drug, Lawyer Says
Novartis’s Alcon Wins Bid to Block Apotex’s Generic Patanol
Teva’s Patents Infringed, U.S. Judge Rules
Risk Panel, Lloyds Capital, Pharma Overtime: Compliance

novartis ag-adr (NVS) Related News

Botox Maker Plans Deep Job Cuts During Takeover Fight
Who Should Pay the Bill for Wonder Drugs?
Big Pharma's Favorite Prescription: Higher Prices
Restrictions on Livestock Antibiotics Don't Worry the Drugmakers
[addPosition2]

novartis ag-adr (NVS) Key Developments

Novartis Announces Earnings Results for the Second Quarter and First Half Ended June 2014; Provides Earnings Guidance for the Full Year of 2014

Novartis announced earnings results for the second quarter and first half ended June 2014. For the quarter, the company reported net sales of $14,637 million, operating income of $3,095 million, net income of $2,585 million or $1.05 per share, core operating income of $3,797 million, core net income of $3,283 million or $1.34 per share, compared to the net sales of $14,488 million, operating income of $2,970 million, net income of $2,548 million or $1.03 per share, core operating income of $3,692 million, core net income of $3,188 million or $1.29 per share for the same quarter a year ago. Free cash flow was $2,413 million compared to $1,785 million a year ago. For the first half, the company reported net sales of $28,659 million, operating income of $6,584 million, net income of $5,553 million or $2.26 per share, core operating income of $7,454 million, core net income of $6,495 million or $2.64 per share, compared to the net sales of $28,233 million, operating income of $5,866 million, net income of $4,970 million or $2.01 per share, core operating income of $7,343 million, core net income of $6,397 million or $2.59 per share for the same period a year ago. As  of the end of June 2014, the net  debt stood at $13.1 billion compared to $8.8 billion at December 31, 2013. The increase of $4.3 billion was driven by the dividend payment of $6.8 billion, share repurchases of $4.3 billion and  other  net  cash  outflow  items  of  $0.1 billion.  This was partially compensated  by the free cash flow of $3.2 billion compared to $3,083 million a year ago, the proceeds from options exercised of $2.4 billion and $1.3 billion of divestment proceeds. The company announced that it was keeping its full-year forecast of a growth in turnover of low to mid-single digits. Group core operating income is expected to grow ahead of sales (cc) in 2014, and now refined to mid to high-single digit (cc).

Google Announces Partnership with Novartis to Develop Innovative Contact Lens

Google has announced a partnership with Novartis to develop a smart contact lens that can monitor the glucose levels in the eye. Google first unveiled the concept in January, which works using tiny sensors and microchips fitted into contact lenses that can then measure and read the amount of glucose in tears, before sending the information to a mobile device so diabetics can manage their condition.

Novartis Launches New Formulation Coartem Tablet in Kenya

Novartis has launched a new formulation of the anti-malaria drug Coartem in Kenya. The Star, the new formation, known as Coartem 80/480, requires patients to consume two tablets for three days, compared with eight pills a day over three days for standard Coartem formulations. The drug may be made available nationwide in Kenya once the government has moved to procure stock. Coartem 80/480 has been approved in Angola, Ghana, Nigeria, and Uganda.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $88.41 USD -0.72

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $89.84 USD -0.70
Merck & Co Inc $58.15 USD -0.06
Roche Holding AG SFr.267.00 CHF -1.20
Sanofi €75.98 EUR -1.34
Procter & Gamble Co/The $79.56 USD -0.70
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 23.7x
Price/Sales 3.6x
Price/Book 3.0x
Price/Cash Flow 24.5x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Novartis Ag-adr - NVS news

3 Mega-Cap Dividend Stock Ideas

Quote:
Read article

US doctor pleads guilty in securities case

Keywords: US doctor pleads guilty in securities case, nvs, pe-and-hedgefunds
Quote:
Read article

Awaiting Novartis acquisition, biotech firm Proteon raises $15.2M

Quote:
Read article

Will Investors Regret Leaving The US?

Keywords: ETFs,Investing,Markets,Stocks,Business,Exchange-traded fund,Forbes,IShares,Research and Analysis,Shares outstanding,Trade
Quote:
Read article

LEAD 1-Nestlé porté par la croissance dans les pays émergents

Quote:
Read article

UPDATE 1-Vectura extends VR315 deal with Sandoz to new areas

Keywords: United States, Will Waterman
Quote:
Read article

Momenta's earnings rise on market grab from Sanofi

Quote:
Read article

[$$] Novartis' MS Pill Questioned by U.K. Regulator

Quote:
Read article

9 Swiss Stocks That May Be a Haven

Quote:
Read article

Advisers steer clients to safer havens in stormy market

Keywords: Greece, Italy, Switzerland, RichardSatran, S&P 500
Quote:
Read article

Vanda Pharmaceuticals reports loss

Quote:
Read article

Swiss stocks - Factors to watch on Aug 5

Quote:
Read article

FDA: Generic biotech drugs require paradigm shift

Keywords: Israel, United States, Michele Gershberg, Phil Berlowitz
Quote:
Read article

UPDATE 2-Vectura gets new U.S. partner for copy of lung drug

Keywords: United States, Andrew Callus
Quote:
Read article

UPDATE 1-Vectura strikes new U.S. deal for lung drug VR315

Keywords: United States
Quote:
Read article

UPDATE 1-Finnish drug maker Orion Q2 meets forecast

Keywords: Switzerland, Jane Merriman
Quote:
Read article

Vanda aims for Argentina

Quote:
Read article

Buyout firms to bid for GSK drugs portfolio-sources

Keywords: Britain, Jane Merriman
Quote:
Read article

PDL posts bigger 2Q profit on lower legal costs

Keywords: PDL posts bigger 2Q profit on lower legal costs, nvs,pdli, earnings
Quote:
Read article

Flu "super antibody" may bring universal shot closer

Quote:
Read article
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.